Legacy Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LEGACY
LEGACY has twenty-four approved drugs.
There are twenty-nine US patents protecting LEGACY drugs.
There are two hundred and seventy-six patent family members on LEGACY drugs in forty-eight countries and two supplementary protection certificates in two countries.
Summary for Legacy
| International Patents: | 276 |
| US Patents: | 29 |
| Tradenames: | 17 |
| Ingredients: | 15 |
| NDAs: | 24 |
Drugs and US Patents for Legacy
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Legacy | NAFTIN | naftifine hydrochloride | GEL;TOPICAL | 204286-001 | Jun 27, 2013 | AB | RX | Yes | Yes | 10,695,303 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Legacy | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | 8,084,475 | ⤷ Start Trial | ⤷ Start Trial | |||
| Legacy | PRAMOSONE | hydrocortisone acetate; pramoxine hydrochloride | CREAM;TOPICAL | 085368-001 | Approved Prior to Jan 1, 1982 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Legacy | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 7,910,610 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Legacy
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Legacy | RIDAURA | auranofin | CAPSULE;ORAL | 018689-001 | May 24, 1985 | 3,708,579 | ⤷ Start Trial |
| Legacy | MOTOFEN HALF-STRENGTH | atropine sulfate; difenoxin hydrochloride | TABLET;ORAL | 017744-001 | Approved Prior to Jan 1, 1982 | 3,646,207 | ⤷ Start Trial |
| Legacy | NAFTIN | naftifine hydrochloride | GEL;TOPICAL | 019356-001 | Jun 18, 1990 | 4,282,251 | ⤷ Start Trial |
| Legacy | ETHYOL | amifostine | INJECTABLE;INJECTION | 020221-002 | Sep 10, 1999 | 5,591,731 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LEGACY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 7.5 mg | ➤ Subscribe | 2014-04-07 |
| ➤ Subscribe | Capsules | 2 mg, 4 mg and 6 mg | ➤ Subscribe | 2007-08-10 |
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-12-02 |
| ➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2004-04-16 |
International Patents for Legacy Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2819967 | ⤷ Start Trial |
| South Korea | 101762465 | ⤷ Start Trial |
| China | 101267810 | ⤷ Start Trial |
| Portugal | 2068881 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Legacy Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | SPC/GB10/012 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 0809498 | 10C0038 | France | ⤷ Start Trial | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
